Search
ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis
He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin. Coverage brought to you by
Dec 7
Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
Oct 22
ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future
John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.
Dec 10, 2024
Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program
John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light....
Jul 1, 2024
.png){kind=logo}
